Journal
TRANSLATIONAL ONCOLOGY
Volume 14, Issue 1, Pages -Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.tranon.2020.100889
Keywords
Small cell lung cancer; Immune checkpoint inhibitors; Combination therapy; atemoradiodierapy; Targeted therapy
Categories
Funding
- Foundation of Educational Commission of Liaoning Province of China [LQNK201714]
- Key Projects of Department of Science and Technology of Liaoning Province [2020JH2/10300142]
- Doctoral Start-up Foundation of Liaoning Province [20170520052]
- Excellent Young Teachers Program of China Medical University [QGZ2018060]
- 345 Talent Project of Shengjing Hospital of China Medical University
Ask authors/readers for more resources
Small cell lung cancer (SCLC) is an aggressive and devastating malignancy, with immunotherapy showing promising progress in the treatment of SCLC patients, especially when combined with other therapies for enhanced therapeutic effects.
Small cell lung cancer (SCLC), an aggressive and devastating malignancy, is characterized by rapid growth and early metastasis. Although most patients respond to first-line chemotherapy, the majority of patients rapidly relapse and have a relatively poor prognosis. Fortunately, immunotherapy, mainly including antibodies that target the cytotoxic T lymphocyte antigen-4 (CTLA-4), checkpoints programmed death-1 (PD-1), and programmed death-ligand 1 (PD-L1) to block immune regulatory checkpoints on tumor cells, immune cells, fibroblasts cells and endothelial cells, has achieved the milestone in several solid tumors, such as melanoma and non-small-cell lung carcinomas (NSCLC). In recent years, immunotherapy has made progress in the treatment of patients with SCLC, while its response rate is relatively low to monotherapy. Interestingly, the combination of immunotherapy with other therapy, such as chemotherapy, radiotherapy, and targeted therapy, preliminarily achieve greater therapeutic effects for treating SCLC. Combining different immunotherapy drugs may act synergistically because of the complementary effects of the two immune checkpoint pathways (ClIA-4 and PD-1/PD-L1 pathways). The incorporation of chemoradiotherapy in immunotherapy may augment antitumor immune responses because chemoradiotherapy can enhance tumor cell immunogenicity by rapidly inducing tumor lysis and releasing tumor antigens. In addition, since immunotherapy drugs and the molecular targets drugs act on different targets and cells, the combination of these drugs may achieve greater therapeutic effects in the treatment of SCLC. In this review, we focused on the completed and ongoing trials of the combination therapy for immunothcrapy of SCLC to find out the rational combination strategies which may improve the outcomes for SCLC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available